Thymagen
- Category
- Bioregulators
- Administration routes
- InjectableNasal
- Regulatory status
- Not FDA-approved
A dipeptide (Glu-Trp) marketed for immune restoration and healthy aging by acting on T lymphocytes and thymic tissue. Immune-restoration evidence remains limited. Anti-aging is supported by animal work, while Western IM862 oncology trials provide human safety and efficacy data but did not establish cancer benefit. Those trials do not establish safety for healthy-aging use. Effects on tumor biology and hormone pathways remain theoretical concerns. It is not an approved drug in the US, and products sold online are unregulated.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
Thymagen (also known as Thymogen) is a synthetic 2-amino-acid peptide originally isolated from Thymalin, a thymus gland extract. Developed by Professor Vladimir Khavinson in Russia and registered as a pharmaceutical in the USSR in 1990, it is one of the earliest Khavinson bioregulatory peptides. Thymagen is designed to support immune function by enhancing T-cell development and reducing inflammation. Interestingly, its mirror-image form (made with D-amino acids) has the opposite effect — suppressing rather than stimulating immunity — and was developed as the separate drug Thymodepressin.
How it works in the body
A dipeptide bioregulator (Glu-Trp) that targets T lymphocytes and thymic epithelial cells. It modulates T cell differentiation by interacting with regulatory elements in genes controlling CD4/CD8 ratios, cytokine production, and the maturation of naive T cells into functional effector cells.
Research overview
Thymagen works primarily by activating T-cell development and maturation, enhancing the immune system's ability to recognize and respond to threats. It also boosts B-cell activity and the germ-killing capacity of neutrophils, while dramatically reducing the inflammatory signal TNF-alpha (by roughly five-fold in lab models). In animal studies, it increased mean lifespan of the longest-lived 10% by about 10%, without increasing overall mean lifespan, and reduced spontaneous cancer rates, cutting blood cancers by 3.4-fold. Clinical studies in Russia report a 94.4% response rate in type 1 diabetes patients with weakened immunity. Approximately 50-80 publications reference Thymagen directly, though most originate from Russian research groups. Western human trials were registered as IM862/oglufanide, including the randomized placebo-controlled trial NCT00002445.
Who researches Thymagen?
Commonly researched by
People researching immune system support
Studied for immune modulation, antiviral, or antimicrobial properties.
People researching inflammation management
Studied for anti-inflammatory effects across various conditions.
People researching longevity and anti-aging interventions
Studied for effects on aging pathways, cellular health, or lifespan extension.
People researching blood sugar regulation
Studied for effects on insulin sensitivity, glucose metabolism, or glycemic control.
People researching liver health
Studied for hepatoprotective effects or liver function support.
Important considerations for
Those who are pregnant or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Anyone under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Those with Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Safety & interactions
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNot recommended for children outside the indications on the Russian label; not approved in the US.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(6)
Rated by level of concern
Limited Western clinical safety data
HighPMID 15598977; https://clinicaltrials.gov/study/NCT00002445
Potential immune over-activation
TheoreticalPMID 12845648; PMID 35408963
Endocrine interactions
TheoreticalPMID 15495616; PMID 19140517
Research-grade product quality concerns (US market)
HighPMID 38732260; PMID 10217204
Unknown long-term effects of chronic use
ModeratePMID 21957588; PMID 11707921
Potential effects on tumor biology
ModeratePMID 15598977; PMID 12845648
Interaction summary(8)
Rated by direction with this peptide
Active Kaposi's sarcoma / antiretroviral therapy context
CautionModerateIn a 202-patient phase III randomized placebo-controlled trial, the same molecule (IM862) given alongside antiretroviral therapy showed no benefit over placebo (response 23% vs 21%, p=0.46) and a significantly shorter median time to tumor progression (16 vs 35 weeks, p=0.012), so combining it with HAART in a patient with active KS has direct human evidence of potential harm.
PMID 15598977; https://clinicaltrials.gov/study/NCT00002445
Immunosuppressants (cyclosporine, tacrolimus, azathioprine, mycophenolate)
CautionTheoreticalDirect pharmacodynamic opposition - Thymogen's stated purpose is T-cell activation and CD4/CD8 normalization, which works against the therapeutic goal in transplant or autoimmune immunosuppression; no interaction study exists, but the mechanistic conflict is unambiguous and the D-isomer of the same dipeptide is marketed precisely as an immunosuppressant.
PMID 38732260
Systemic corticosteroids
CautionTheoreticalGlucocorticoids are thymolytic and suppress T-cell maturation, plausibly blunting Thymogen's thymic-epithelial and T-differentiation effects while Thymogen may partially counteract intended steroid immunosuppression; no clinical interaction data exist in either direction.
Mechanism-based (no interaction study identified)
Antifungal therapy (nystatin, azoles) in candidiasis
SynergisticLowThymogen was used as an immunocorrector adjunct to lymphotropic antifungal therapy in 52 patients with oral mucosal candidiasis with normalized mucosa and reduced yeast colonization, and cleared fungal infection in an immunodepressed animal model, though the uncontrolled designs cannot separate the peptide's contribution from the antifungal.
PMID 8992656; PMID 2337388
Standard anti-tuberculosis chemotherapy
SynergisticLowIn destructive pulmonary tuberculosis, Thymogen added to anti-TB regimens reportedly stimulated the T-cell link, improved tolerance to anti-TB drugs, and accelerated cavity healing and sputum conversion (open-label Russian data only).
PMID 10605346; PMID 10067345
Interferon inducers (e.g., cycloferon)
SynergisticLowCombined cycloferon plus Thymogen normalized immune-status parameters and was associated with a more favorable postoperative course in uterine cancer surgery, consistent with reviews classifying thymic dipeptides among interferon-inducing immunomodulators; evidence is observational, not randomized.
PMID 16786663; PMID 19355963
Thyroid medications (levothyroxine, thiamazole/mercazolyl)
SynergisticTheoreticalThyroid status modulates the response - in experimental hypothyroidism the immunotropic effect of immunomodulators including Thymogen was substantially greater once thyroid function was compensated, and Thymogen altered L-thyroxine-associated brain water content in a rat toxic-edema model; direction is favorable in these animal models but no human data exist, so treat thyroid-replaced patients as an untested population rather than an established synergy.
PMID 15495616; PMID 19140517
ACE inhibitors and antihypertensives
CautionTheoreticalGlu-Trp (EW) itself showed measurable ACE-inhibitory activity in human umbilical vein endothelial cells and blocked angiotensin I-induced vasoconstriction in rat aorta, raising a theoretical additive blood-pressure-lowering effect; EW was less potent than Ile-Trp and no in-vivo blood pressure effect was demonstrated for EW specifically.
PMID 28102435
Known risks(6)
Limited Western clinical safety data
ModerateWhile Thymogen has been used as a registered pharmaceutical in Russia since 1990 with reports of minimal side effects, the safety data has not been independently validated through Western regulatory processes. Russian clinical reports state that 'thymalin and thymogen have practically no side effects,' but this has not been confirmed in large, well-controlled studies meeting FDA or EMA standards.
Potential immune over-activation
ModerateAs an immunostimulant, Thymagen could theoretically exacerbate autoimmune conditions by enhancing T-cell differentiation and immune cell activation. Individuals with autoimmune diseases, organ transplants, or other conditions requiring immunosuppression should exercise extreme caution.
Endocrine interactions
Low-ModerateRussian pharmaceutical literature notes relative contraindications including the perimenstrual period, pituitary adenoma, acromegaly, and use during the period of physiological thymic activity up to puberty. Synergistic effects have been noted with pituitary hormones (somatotropin, luteinizing hormone) and estrogens.
Research-grade product quality concerns (US market)
ModerateIn the US, Thymagen is sold only as unregulated products online. Unregulated products sold online lack pharmaceutical-grade quality controls, sterility assurance, and endotoxin testing required for injectable medications. Self-administration carries infection and contamination risks.
Unknown long-term effects of chronic use
The longest controlled study (Anisimov & Khavinson 2001) treated rats for 12 months, showing anti-aging benefits. However, long-term effects of chronic Thymagen use in humans are not well-characterized. Effects on immune homeostasis, cancer surveillance, and endocrine function over years of use remain unknown.
Potential effects on tumor biology
Low (potentially beneficial)Preclinical data shows Thymagen reduces spontaneous carcinogenesis and inhibits tumor growth via NK cell activation. However, as an immune modulator that affects cell proliferation and cytokine networks, effects on pre-existing cancers or cancer subtypes not mediated by NK cells are unpredictable.
Drug interactions(6)
Immunosuppressants (cyclosporine, tacrolimus, mycophenolate, corticosteroids)
Theoretical antagonistic interaction. Thymagen stimulates T-cell differentiation and immune activation, which directly opposes the mechanism of immunosuppressive drugs. Combined use could reduce immunosuppressant efficacy and increase transplant rejection risk. Contraindicated in organ transplant recipients.
Pituitary hormones (somatotropin, luteinizing hormone) and estrogens
Documented synergistic effects. Russian pharmaceutical literature reports that thymic peptide bioregulators have synergistic interactions with pituitary gland hormones and estrogens, potentially amplifying both immune and endocrine effects. Combined use may require dose adjustment.
Sex hormones (progestins, androgens) and adrenal corticosteroids
Documented antagonistic effects. Russian literature notes that progestins, androgens, and adrenal hormones act as antagonists to thymic peptide bioregulators, potentially reducing Thymagen's immunostimulatory efficacy.
Other immunostimulants (interferons, interleukins, colony-stimulating factors)
Theoretical additive immune stimulation. Combining Thymagen with other immunostimulatory agents could produce excessive immune activation. The 2003 knockout mouse study showed Thymagen's activity is partly IL-12-dependent, suggesting potential interaction with IL-12-based therapies.
Cancer immunotherapies (checkpoint inhibitors, CAR-T)
Theoretical — unknown interaction profile. Thymagen enhances NK cell cytolytic activity and T-cell function, which could theoretically augment or complicate immunotherapy responses. No clinical data available. Use with cancer immunotherapies should only be considered under strict medical supervision.
Anti-coagulants and fibrinolytics
Theoretical interaction. Thymalin-derived peptides (including Thymagen/EW) have been reported to normalize coagulation and fibrinolytic activity. Combined use with anticoagulants (warfarin, heparin, DOACs) could theoretically affect bleeding risk. No direct clinical data.
Research & benefits
Evidence base
- Evidence Level
- Mostly Preclinical
- Total Studies
- 65
- Human Studies
- 8
Thymagen's clinical evidence is limited and comes almost entirely from Russian clinical studies published in Russian-language journals between 1990-2015. A clinical study in type 1 diabetes patients showed a 94.4% clinical response rate for immunocorrection. Additional clinical experience includes treatment of candidiasis, inflammatory gynecological diseases, and viral infections. In Russia, Thymogen has been used clinically since 1990 as a registered pharmaceutical. None of these studies have been replicated in large, randomized, double-blind Western clinical trials, and the evidence has not been independently validated outside of the Russian research ecosystem. Human evidence also includes a 202-patient Western placebo-controlled phase III trial of IM862/oglufanide that found no superiority in AIDS-related Kaposi sarcoma and possible earlier progression; the Russian surgical trial addresses a different indication. The cited longevity study was in rats; reproducibility and human benefit are not established.
Researched for(8)
Rated by confidence in the evidence
Immune system restoration and T-cell activation
MediumMultiple human studies, including one placebo-controlled trial, show T-cell restoration across conditions.
PMID 21957588; PMID 10605346; PMID 12506630; PMID 12918362
Anti-aging and lifespan extension
LowSingle rat study showed longer maximum lifespan, not yet tested in humans.
PMID 11707921; PMID 24003726
Anti-tumor activity and reduced spontaneous carcinogenesis
LowReduced tumor incidence in rats, but the same dipeptide failed in several human cancer trials.
PMID 11707921; PMID 12845648; PMID 15598977 (NCT00002445); PMID 15354209; NCT00006037; NCT00017303
Anti-inflammatory and TNF-alpha suppression
SpeculativeBased on one lab-dish study, with no animal or human inflammation data yet.
PMID 35408963
Immunocorrection in secondary immunodeficiency (type 1 diabetes)
SpeculativeOne small uncontrolled study in diabetics reported high response rates, unreplicated and unblinded.
PMID 9026934; PMID 15311693
Reduced severity of fungal infections under immunodepression
LowAnimal data plus one uncontrolled human case series, confounded by concurrent antifungal treatment.
PMID 2337388; PMID 8992656
Perioperative immune restoration in elderly patients
MediumOne small randomized, placebo-controlled trial in elderly surgical patients, not independently replicated.
PMID 21957588; PMID 16786663
Hepatoprotective and antioxidant effects (via analogues)
LowRat studies support liver protection, but mostly test chemical analogues, not the original peptide.
PMID 40442470; PMID 37861903; PMID 12227096
Benefits(8)
Immune system restoration and T-cell activation
Anisimov & Khavinson 2000 (Biogerontology, PMID 11707921) — Thymagen activated T-cell differentiation, T-cell recognition of peptide-MHC complexes, and neutrophilic chemotaxis and phagocytosis in rats. Smirnov et al. 2011 (PMID 21957588) — double-blind, randomized, placebo-controlled study showed thymogen restored structural and functional parameters of cellular immunity in elderly surgical patients.
Anti-aging and lifespan extension
Anisimov & Khavinson 2000 (Biogerontology, PMID 11707921) — Mean lifespan of the longest-lived 10% was 949 days in controls versus 1048 days in treated rats; overall mean lifespan was unchanged. Aging rate (Gompertz alpha) was 0.0071/day in controls vs. 0.0041/day in the treated group, representing a 42% reduction in biological aging rate.
Anti-tumor activity and reduced spontaneous carcinogenesis
Anisimov & Khavinson 2000 (Biogerontology, PMID 11707921) — Total tumor incidence 1.5x lower, malignant tumors 1.7x lower, hematopoietic malignancies 3.4x lower vs. controls (P < 0.02). Smith et al. 2003 (Int J Cancer, PMID 12845648) — L-Glu-L-Trp inhibited tumor growth in mice via NK cell cytolytic activity dependent on perforin and partly on IL-12.
Anti-inflammatory and TNF-alpha suppression
Avolio et al. 2022 (Int J Mol Sci, PMID 35408963) — Thymogen acted as a natural inducer of TNF tolerance in monocytes and as an anti-inflammatory molecule in macrophages during LPS-mediated inflammatory activity. TNF-alpha synthesis reduced approximately five-fold in LPS-induced inflammation models.
Immunocorrection in secondary immunodeficiency (type 1 diabetes)
Zhuk & Galenok 1996 (PMID 9026934) — Clinical trial in type 1 diabetes patients with secondary immunodeficiency. Thymogen removed signs of secondary immunodeficiency via activation of T-lymphocyte differentiation. Clinical effect in 94.4% of patients, laboratory improvement in 83.3%.
Reduced severity of fungal infections under immunodepression
Khmel'nitskii et al. 1990 (PMID 2337388) — Thymogen injections reduced severity of candidiasis under immunodepression by activating the immunocompetent system including thymus, favoring disappearance of the fungal infection.
Perioperative immune restoration in elderly patients
Smirnov et al. 2011 (PMID 21957588) — Double-blind, randomized, placebo-controlled study: intranasal Thymogen (100 mcg/day for 7 days preoperatively) in elderly patients with abdominal tumors restored cellular immunity, significantly decreased postoperative complications, and shortened the postoperative period.
Hepatoprotective and antioxidant effects (via analogues)
Zhilinkova et al. 2023 (Bull Exp Biol Med) — Thymogen and its D-alanine-modified analogues suppressed oxidative peroxidation and stimulated reparative regeneration of hepatocytes in acute toxic hepatopathy models.
Key studies(5)
Immunomodulatory synthetic dipeptide L-Glu-L-Trp slows down aging and inhibits spontaneous carcinogenesis in rats
Original research (preclinical, long-term in vivo)76 outbred female rats (44 treated, 32 controls)12 months of treatment, lifetime observationAnisimov VN, Khavinson VK, Morozov VG
Biogerontology
2000
L-Glu-L-Trp (5 mcg/rat, SC, 5x/week for 12 months) increased mean lifespan of the longest-lived 10% from 949 to 1048 days (overall mean lifespan was unchanged), reduced Gompertz aging rate by 42%, and decreased total tumor incidence 1.5x, malignant tumors 1.7x, and hematopoietic malignancies 3.4x vs. controls. This rat study is the main basis for the dipeptide's anti-aging and anti-cancer claims.
Natural killer cell cytolytic activity is necessary for in vivo antitumor activity of the dipeptide L-glutamyl-L-tryptophan
Original research (preclinical, mechanistic)Multiple mouse cohorts including knockout modelsVariousSmith DL, Cai J, Zhu ST, Wei W, Fukumoto J, Sharma S, Masood R, Gill PS
International Journal of Cancer
2003
L-Glu-L-Trp inhibited tumor growth in mice without direct cytotoxicity to tumor cells. Antitumor activity required NK cell perforin-dependent cytolysis and was partly dependent on IL-12 but independent of IFN-gamma. First mechanistic demonstration that Thymagen's anti-cancer effects are immune-mediated via NK/NKT cell activation.
Application of Thymogen for preoperative preparation of elderly patients with tumor processes in abdominal cavity
Double-blind, randomized, placebo-controlled clinical trialElderly patients with abdominal/retroperitoneal solid tumors7 days preoperative intranasal administration (100 mcg/day)Smirnov VS, et al.
Advances in Gerontology (Russian)
2011
Preoperative intranasal Thymogen restored structural and functional parameters of cellular immunity, led to a statistically significant decrease in the number and range of postoperative complications, and shortened the postoperative period vs. placebo. Strongest clinical evidence for Thymagen from a Western-standard study design.
Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line
Original research (in vitro, mechanistic)THP-1 cell line experiments with 5 Khavinson peptidesIn vitroAvolio F, Martinotti S, Khavinson VK, Esposito JE, Giambuzzi G, et al.
International Journal of Molecular Sciences
2022
Thymogen and four other Khavinson peptides cooperated as natural inducers of TNF tolerance in monocytes and acted on macrophages as anti-inflammatory molecules during LPS-mediated inflammatory activity. All five peptides modulated key proliferative patterns, increasing tyrosine phosphorylation of mitogen-activated cytoplasmic kinases.
The First Reciprocal Activities of Chiral Peptide Pharmaceuticals: Thymogen and Thymodepressin, as Examples
ReviewComprehensive review of L-Glu-L-Trp and D-Glu-D-TrpDeigin V, Linkova N, Vinogradova J, et al.
International Journal of Molecular Sciences
2024
Reviewed the first examples of up-and-down homeostasis regulation by two enantiomeric drugs: immunostimulant Thymogen (L-Glu-L-Trp) and immunosuppressor Thymodepressin (D-Glu-D-Trp). Reversal of both chiral centers produced reciprocal biological activity — a fundamental finding in peptide pharmacology.
Regulation & availability
Why researchers look at it
One rat study found a roughly 10% increase in mean lifespan of the longest-lived 10% (overall mean lifespan was unchanged) and a 3.4-fold reduction in spontaneous blood cancers, and a double-blind RCT in elderly surgical patients demonstrated immune restoration and reduced postoperative complications. As possibly the simplest bioactive peptide — just two amino acids — it has been a registered pharmaceutical in Russia since 1990. Independent Western trials could establish whether these animal longevity results translate to humans.
- Estimated cost
- $30-80/mo oral capsules
- FDA status
- Not FDA-approved for any indication. No current IND was publicly verified; public approval records cannot establish that an IND was never submitted. The dipeptide also underwent Western clinical investigation as IM862/oglufanide disodium. No qualifying basis for routine compounding from bulk under 503A or 503B was identified. Thymogen has been a registered pharmaceutical in the Russian Federation since 1990, approved by the Russian Ministry of Health for immunocorrection, but Russian medicinal registration does not confer U.S. approval.
- WADA status
- Not specifically named in the WADA 2026 Prohibited List. S0 concerns pharmacological substances without current therapeutic approval by any governmental health authority; it does not exclude Russian approvals. Russian Thymogen medicinal approval therefore contradicts an S0 rationale based on lack of approval. A compound-specific classification was not confirmed; athletes should obtain a determination from their anti-doping organization.
- Prescribability
- Not an FDA-approved medication in the United States. No qualifying basis for routine compounding from bulk under 503A or 503B was identified; Thymagen/Thymogen is absent from the published interim-category lists. In Russia, Thymogen has been a registered medicine since 1990, approved by the Russian Ministry of Health for correction of immune functions, with nasal and intramuscular formulations; injection is prescription-only. Western clinical trials occurred under IM862/oglufanide.
- Availability
- In Russia and some CIS countries, Thymogen is marketed as a registered medicine in nasal (Thymogen Spray) and intramuscular formulations. The injectable product requires a prescription; nonprescription access must not be generalized across formulations. In the United States and Western countries, Thymagen is not available as an approved pharmaceutical: no FDA-approved U.S. product or qualifying routine bulk-compounding basis was identified. Some integrative medicine clinics may offer Thymagen, but an offering does not establish approval or lawful bulk compounding. EU authorization and country-specific access exceptions require separate verification.
International status
EU
Not approved
US
Not approved
Russia
Used clinically (Khavinson bioregulator protocol)
Worldwide
Limited to Russian clinical use
Regulatory timeline(12)
- 1970sVladimir Khavinson and V.G. Morozov begin isolating peptide complexes from animal thymus glands at the Military Medical Academy in Leningrad (now St. Petersburg), initially for Soviet military research programs.
- 1982-1985Thymalin (the parent polypeptide complex) is registered as a pharmaceutical in the USSR for immunocorrection. The active dipeptide Glu-Trp is isolated from Thymalin by RP-HPLC and subsequently synthesized.
- 1990Synthetic dipeptide L-Glu-L-Trp is registered as the pharmaceutical 'Thymogen' in the USSR. Khavinson receives the USSR Council of Ministers' Prize for introducing peptide bioregulators into healthcare. Thymogen becomes one of six registered Khavinson peptide pharmaceuticals.
- 1990Khmel'nitskii et al. publish study on Thymogen's effect on immune system in candidiasis under immunodepression (PMID 2337388), part of early clinical validation.
- 1996Zhuk & Galenok publish clinical study of Thymogen in type 1 diabetes mellitus showing 94.4% clinical effect for immunocorrection (PMID 9026934).
- 2000Anisimov & Khavinson publish landmark study in Biogerontology showing L-Glu-L-Trp extends lifespan and inhibits carcinogenesis in rats (PMID 11707921). First major English-language publication establishing anti-aging properties.
- 2003Smith et al. publish mechanistic study demonstrating Thymagen's antitumor activity requires NK cell perforin-dependent cytolysis (PMID 12845648).
- 2011Smirnov et al. publish double-blind RCT of intranasal Thymogen in elderly surgical patients showing immune restoration and reduced postoperative complications (PMID 21957588).
- 2020Khavinson et al. publish proposal for using peptide bioregulators (including Thymogen) in COVID-19 complex therapy (MDPI Molecules, PMC7583759).
- 2022Avolio et al. publish study showing Thymogen acts as anti-inflammatory molecule and TNF tolerance inducer in human monocyte/macrophage cell line (PMID 35408963).
- 2024Deigin et al. publish review on reciprocal chiral activities of Thymogen (immunostimulant) and Thymodepressin (immunosuppressant) — the first characterized pair of enantiomeric peptide pharmaceuticals (PMID 38732260).
- 2026-presentThymogen remains a registered medicine in Russia, with no FDA-approved product identified. Western oncology trials were registered under IM862/oglufanide, including NCT00002445. Current IND status was not publicly verified.
Sources & FAQs
Research sources(16)
- Anisimov & Khavinson 2000 — L-Glu-L-Trp slows aging and inhibits carcinogenesis in rats
- Smith et al. 2003 — NK cell cytolytic activity required for L-Glu-L-Trp antitumor effects
- Khmel'nitskii et al. 1990 — Thymogen effect on immune system in candidiasis under immunodepression
- Zhuk & Galenok 1996 — Thymogen in treatment of type-1 diabetes mellitus
- Smirnov et al. 2011 — Thymogen preoperative preparation in elderly tumor patients (RCT)
- Avolio et al. 2022 — Peptides regulating proliferative and inflammatory pathways in THP-1 cells
- Deigin et al. 2024 — Reciprocal chiral activities of Thymogen and Thymodepressin
- Khavinson & Popovich 2021 — Peptide Regulation of Gene Expression: Systematic Review
- Kuznik et al. 2021 — Thymalin for immunocorrection and molecular aspects of biological activity (PMC review)
- Khavinson et al. 2020 — Peptides: Prospects for Use in Treatment of COVID-19
- Chervyakova, Linkova et al. 2014 — Age-related molecular aspects of immunomodulating activity in the spleen
- Zakharova et al. 1997 — Natural and synthetic thymic peptides as therapeutics for immune dysfunction
- PubChem — Thymogen compound data (CID 100094)
- WADA 2026 Prohibited List
- Vladimir Khavinson — Wikipedia biographical page
- Linkova et al. 2017 — Molecular aspects of immunoprotective activity of peptides in spleen during aging
Frequently asked questions(5)
What is the difference between Thymagen, Thymalin, and Thymosin Alpha-1?
These are three distinct thymic peptides. Thymalin is a polypeptide complex (multiple peptides) extracted from calf thymus glands — it is the parent compound from which Thymagen was isolated. Thymagen (Thymogen) is a single synthetic dipeptide (Glu-Trp) identified as one of the active immunomodulatory components of Thymalin. Thymosin Alpha-1 (Ta1) is a completely different 28-amino-acid peptide originally isolated from Thymosin Fraction 5 by Allan Goldstein at George Washington University. Ta1 has much more extensive Western clinical data, including approval in over 30 countries for hepatitis B. All three modulate immunity but through different mechanisms and with vastly different levels of clinical evidence.
Has Thymagen been tested in human clinical trials?
Yes, but primarily in Russian clinical studies. A double-blind, randomized, placebo-controlled trial (Smirnov et al. 2011) tested intranasal Thymogen in elderly cancer surgery patients and showed immune restoration and reduced postoperative complications. Another study in type 1 diabetes patients showed 94.4% clinical response rate for immunocorrection. Western oncology trials were registered under IM862/oglufanide; they do not establish immune-restoration or anti-aging benefits. The clinical evidence is limited by small sample sizes and publication primarily in Russian-language journals.
How does the chirality of Thymagen affect its function?
This is one of the most fascinating aspects of Thymagen pharmacology. The natural L-form (L-Glu-L-Trp, Thymogen) is an immunostimulant — it activates T-cells, enhances immune function, and promotes immune restoration. The D-form (D-Glu-D-Trp, Thymodepressin) has the exact opposite effect: it suppresses immune function and is used as an immunosuppressive drug. This reciprocal chiral activity was described in a 2024 review by Deigin et al. (PMID 38732260) and represents a rare example of enantiomeric peptide drugs with opposing pharmacological profiles.
Is Thymagen the same as the Russian nasal spray Thymogen?
Yes, they are the same molecule. The Russian nasal spray formulation (Thymogen Spray) delivers the same Glu-Trp dipeptide intranasally.
Can Thymagen help with COVID-19 or other viral infections?
Russian researchers have proposed that Thymagen and its parent compound Thymalin could be effective in complex therapy for COVID-19 (Khavinson et al. 2020, MDPI Molecules). The rationale is that immunoprotective peptides may help prevent the 'cytokine storm' seen in severe COVID-19 by regulating immune homeostasis rather than simply suppressing or stimulating immunity. Thymalin has been used in Russia for pneumonia of various etiologies, and its component peptides (including Thymagen/EW) normalize coagulation and fibrinolytic activity. However, no controlled clinical trials have specifically tested Thymagen for COVID-19 or any other viral infection in a Western regulatory framework.